CMTM4 can effectively protect programmed death-ligand 1 (PD-L1) as a target for lysosomal degradation and prevent the clearance of tumor cells by immune cells, suggesting that CMTM4 plays an important role in tumor immunotherapy (Chui et al., 2022; Mezzadra et al., 2017; Zhang et al., 2022a). The gene discussed is CMTM4; the disease is neoplasm.